LRMR (Larimar Therapeutics) Short-Term Debt: $0.00 Mil (As of Mar. 2026)


LRMR Larimar Therapeutics Inc LRMR
34 GF Score
Price $4.29
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Short-Term Debt?

Larimar Therapeutics LRMR +3.63% 34 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates LRMR with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Larimar Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Larimar Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Larimar Therapeutics Short-Term Debt Related Terms

Larimar Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics Short-Term Debt Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LRMR
34GF Score
Larimar Therapeutics Inc LRMR
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Larimar Therapeutics (LRMR) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Larimar Therapeutics' Short-Term Debt too high?
Larimar Therapeutics' current Short-Term Debt is $0.00 Mil. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Short-Term Debt compare to XFOR and CMPX?
Larimar Therapeutics' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Larimar Therapeutics's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (LRMR) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Larimar Therapeutics (LRMR), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges ZA71:Germany
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score

Get the complete analysis for LRMR

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.29
Price